Cha Vaccine Institute is showing strong performance. This appears to be influenced by the news that the American Association for Cancer Research (AACR) announced preclinical results of the immuno-oncology drug ‘CVI-CT-001’ administered in combination with existing anticancer agents such as immune checkpoint inhibitors and chemotherapy.
As of 10:50 AM on the 18th, Cha Vaccine Institute was trading at 4,990 KRW, up 475 KRW (10.52%) compared to the previous trading day.
CVI-CT-001 is an immuno-oncology drug developed independently by Cha Vaccine Institute using the immune adjuvant L-pampo. It induces cancer cell death and transforms the tumor microenvironment from low immunogenicity to high immunogenicity.
At AACR, Cha Vaccine Institute revealed the anticancer effects of CVI-CT-001 administered to animal models of △ low-immunogenic colorectal cancer and △ triple-negative breast cancer, which is low-immunogenic and poorly responsive to immune checkpoint inhibitors.
In colorectal cancer, CVI-CT-001 and the immune checkpoint inhibitors anti-PD-1 and anti-CTLA-4 were administered separately. Tumor size analysis showed that tumors decreased by 87.3% with CVI-CT-001 treatment, whereas immune checkpoint inhibitors reduced tumors by only 17.3% and 23.6%, respectively. Additionally, subjects treated with a combination of the two immune checkpoint inhibitors survived for 47 days, but those treated with a triple combination including CVI-CT-001 survived for more than 60 days.
Yeom Jeong-seon, CEO of Cha Vaccine Institute, stated, “In this study, we confirmed that CVI-CT-001 showed equal or greater efficacy compared to first-line chemotherapy while exhibiting lower toxicity. Both immune checkpoint inhibitors and chemotherapy have limitations, but CVI-CT-001 can complement these shortcomings, confirming the possibility of using it in combination therapy with existing anticancer drugs.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
